Monsanto offered to acquire the company at a price of 449 Swiss francs per Syngenta share, with approximately 45% of the price paid in cash. However, Syngenta's management decided against negotiations. Hikma Pharmaceuticals PLC closed 4.32 short of its 52-week high (21.37), which the company reached on March 25. Affimed Therapeutics. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Morning 4: Dearborn woman facing decades in prison for $65M pharmaceutical coupon scheme -- and other news tweet in which Musk claimed he had lined up financing to $2.00 per CVR upon achievement of net sales of OPNT003 of $300 million or more during any period of four consecutive quarters prior to the seventh anniversary of the U.S. commercial launch of OPNT003. Cost basis and return based on previous market day close. With the lower re-negotiated a lower price of $21.5 billion between Johnson & Johnson and Guidant, Boston Scientific announced an unsolicited offer of $24.6 billion for Guidant (an offer of $72 per share of Guidant, $36 in cash and a fixed number of Boston Scientific shares valued at $36 a share). And although the talk of tax inversions has cooled, its worth noting that both these pharma companies are located in the tax-friendly country of Ireland. This includes its focus on next-generation narcolepsy treatments. This is largely because cash is easy to raise, from public and private investors alike, leaving sellers with little incentive to negotiate anything other than gold-plated terms. Tepezza had generated nearly $1.5 billion in the nine months ended Sept. 30, a growth of 37% from last year, while Krystexxa garnered $500 million, up 27% from the prior year. Pour en savoir plus sur notre utilisation de vos informations, veuillez consulter notre Politique relative la vie prive et notre Politique en matire de cookies. The push included direct pressure from Pfizer partner BioNTech to censor activists demanding low-cost generic vaccines for low-income countries, Fang wrote. The final analysis here is interesting because it shows that, despite climbing premiums, the average size of a biopharma M&Adeal has not gone in the same direction; on a median basis they have actually got smaller. Alnylam's Strategy Is Getting Bigger. But takeover talk has largely cooled down since late last year. However they later re-negotiated a lower price of $21.5 billion. Jazz Pharmaceutical, with a market cap of $8.42 billion, is a much larger company and has the money to devote to GW Pharmaceuticals to make it a profitable segment and deal with any short-term issues GW Pharmaceuticals may have. offer to sell or the solicitation of an offer to buy any security. Here are two companies that could follow Salix Pharmaceuticals as targets in the pharma M&A boom. The company has gone from making a reported $15 million in revenue in 2018 to $311 million in 2019, and recently said it expects to bring in $526 million in 2020, a huge rise in just two years. Both companies are looking for treatments for movement disorders, among other things. ET, 3 Top Marijuana Stocks to Buy for the Long Haul, This Exciting Growth Sector Is Predicted to Keep Doubling Until 2028, Why Jazz Pharmaceuticals Stock Rose 13.3% in March, Social Security: 4 Big Changes Washington Wants to Make, Warren Buffett Is Raking in $4.84 Billion in Annual Dividend Income From These 6 Stocks, 3 High-Growth Stocks That Could Be Worth $1 Trillion in 10 Years -- or Sooner, History Suggests the S&P 500 Could Soar in 2023. The uncertainties wrought by a global pandemic have seemingly failed to transfer any power back to acquirers, and those with desirable assets look set to remain in a very strong position. That's when a firm buys out a competitor to shut it down to slow down or prevent competition. This cut of the data was performed on the same cohort as above, so only transactions above $500m. The rapid pace of innovation in biopharma has produced a target-rich environment. Cost basis and return based on previous market day close. GW Pharmaceuticals' stock shot up immediately after the announcement and on Thursday, was trading only seven dollars lower than what Jazz is offering for its stock. This is likely a decent investment even if Opiant Pharmaceuticals, Inc. is 80% likely not to achieve even the first milestone paying out $2. Through nine months, it lost $28,981 million in net income, compared to positive net income of $15 million in the same period in 2019. Indivior is laying out $20 in cash and a contingent value right that's potentially worth up to $8 per share. While about two dozen companies showed some interest in Pandion's work between 2018 and 2020, only Merck and one other "global pharmaceutical company" made formal acquisition or partnership proposals. The fact of the matter is Wall Street has little to no patience when it comes to potential blockbusters stumbling out of the gate. Making the world smarter, happier, and richer. The oral spray, which contains both CBD and THC, is already approved in the U.K. as a therapy for various multiple sclerosis (MS) symptoms, especially MS-related spasticity (muscle spasms or stiffness). Data is a real-time snapshot *Data is delayed at least 15 minutes. Indivior has around a billion dollars in cash and investments and a favorable free cash flow profile. The top ten deals in the industry totaled $97 billion in 2020, led by the $39-billion buyout of Alexion Pharmaceuticals - Get Free Report late in the year by AstraZeneca - Get SAN DIEGO, January 17, 2023--SFJ Pharmaceuticals ("SFJ" or the "company") today announced the closing of the sale and transfer of assets related to Bentracimab from Amgen spent $3.7 billion on a deal earlier this month for ChemoCentryx in order to attain the newly approved ANCA-associated vasculitis drug Tavneos. A 2nd request means the antitrust authorities would look into the deal more profoundly, and it means things take a lot longer. While M&A was plentiful in 2018 and 2019, and even held up during a year gripped by the coronavirus pandemic, 2021 was much quieter. Jazz is a neuroscience company and so is GW Pharmaceuticals. In a report earlier this month, RBC My understanding is that victims sometimes require 2-4 applications of Naxolone. This isn't likely to be a killer acquisition that regulators don't like. Source: Portola Pharmaceuticals Together the two drugs are expected to have blockbuster sales combined of over $5 billion annually in a market expected to substantially grow. They just approach similar diseases with different therapies. Recall that it was willing to fork out close to $70 billion for Allergan just a couple of months ago. I love to get a CVR during a takeover process. Clicca su Gestisci impostazioni per maggiori informazioni e per gestire le tue scelte. There is simply too much interest from pharma heavyweights such as Pfizer, Eli Lilly, among others, in novel psych drugs. Aurinia Pharmaceuticals hired a trio of executives in a move that suggests it's nowhere near a buyout and AUPH stock plummeted Friday.. X. That could boost sales by a lot. Amgen spent $3.7 billion on a deal Get the free daily newsletter read by industry experts. 3 Can't-Miss Biotech Events Coming Up in 2022, Alnylam Pharmaceuticals, inc (ALNY) Q3 2021 Earnings Call Transcript, Social Security: 4 Big Changes Washington Wants to Make, Warren Buffett Is Raking in $4.84 Billion in Annual Dividend Income From These 6 Stocks, 3 High-Growth Stocks That Could Be Worth $1 Trillion in 10 Years -- or Sooner, History Suggests the S&P 500 Could Soar in 2023. With that, the natural question is this: What company is the next buyout target? The target looks ambitious but certainly not impossible to me. Get market updates, educational videos, webinars, and stock analysis. Merck, under outgoing CEO Ken Frazierand now retired research chief Roger Perlmutter, has stayed away from large-scale dealmaking. Transactions are recorded by the highest Despite COVID-19, sales of Epidiolex were up more than 70% in 2020. Learn how to trade stocks like a pro with just 3 email lessons! Habig will lead Aurinia's commercial efforts, including sales of its one commercial product, a treatment for lupus nephritis called Lupkynis. February started off with Pfizer (NYSE: PFE) buying up Hospira (NYSE: HSP) for $15 billion. Over the course of more than a year, Pandion turned down Merck's offers to license its research, set up a 50-50 partnership and twice acquire the company,before agreeing to be bought for $60 per share. Mallinckrodt plc MNK announced that it has acquired privately-held InfaCare Pharmaceutical Corporation.. Most Trusted Financial Companies Take A Survey And Win A $50 Amazon Gift Card. *Average returns of all recommendations since inception. I wrote this article myself, and it expresses my own opinions. In order for the hostile takeover to go through successfully, Mylan needed 50% of Perrigos shares to be tendered under the deal. The pharma industry knocked off the tech industry to take the No. 1/17/2023 They are always uniquely structured which makes them a little bit of a headache to figure out. Before that, reports said Bristol Myers could be negotiating a deal. There's a special meeting of stockholders on March 1, and I'd expect the deal to close out soon after, provided HSR runs out without any issues. In 2018 I founded Starshot Capital B.V. A Dutch AIF manager. Through the first nine months of 2020, the company reported $378.6 million in revenue, up 88% year over year. Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) is a nano-cap pharma that's being acquired by small-cap pharma Indivior PLC (OTCPK:INVVY). Karuna Therapeutics (KRTX -2.83%) posted outstanding late-stage trial results earlier this month for its schizophrenia drug candidate KarXT (xanomeline-trospium). The hirings likely cooled investors' expectations that Aurinia could be looking for a buyout. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services. We want to hear from you. Follow Allison Gatlin on Twitter at @IBD_AGatlin. The average takeout premium for biopharma M&A deals this year is sitting just below 2019s record, which tipped into triple figures, an Evaluate Vantage analysis finds. OPNT003 is a drug that would be used to treat people with a Fentanyl overdose. Authors may own the stocks they discuss. All Rights Reserved. Biotech Stocks To Watch And Pharma Industry News, Leading Health Stock With Rising Earnings Estimates Nears Buy Point, Novartis ADR Meets 80-Plus Relative Strength Rating Benchmark, Stock Upgrades: Novartis ADR Shows Rising Relative Strength, HALO Stock: Halozyme Gets Under Your Skin To Deliver Blockbuster Drugs And Booming Growth, Biopharma Bristol-Myers Unfazed By Generic Competition For Cancer Cash Cow, Bristol Myers Relies On 'Mature' Products For Narrow Quarterly Beat, Novartis Offers Mixed Earnings Report As It Approaches A Key Spinoff. Thats roughly six times bigger than the average yield of the Dow. Colao formed Aurinia's commercial organization and helped launch Lupkynis last year. Second bid, unanimously rejected by the Shire Board, who concluded that it significantly undervalue the Company, its growth prospects as well as pipeline. Now, there is a major impediment to a potential buyout in this case. Aurinia Pharmaceuticals $AUPH Stock Up On Buyout Rumors January 21, 2022 Analysts Activity / Biotechnology 5 mins read Get Email Alerts and Follow Us: Buyout rumors The following table lists the largest mergers and acquisitions in the pharmaceutical and biotechnology industry (those over $10 billion). If you can get them cheap enough, they can be really attractive. Treatments for overdoses (Opiant pharmaceuticals). However, this acquisition has since been much derided after Synageva's lead drug, Kanuma, fell well short of Alexion's blockbuster hopes. OPNT also has financial backing and collaborates with U.S. government agencies, which is a soft sign that there is at least governmental/societal interest in getting its product out there. Moreover, these gene-silencing drugs have an unusually strong competitive moat due to their unique nature and outstanding clinical profiles. Opiant Pharmaceuticals, Inc. ( NASDAQ: OPNT) is a nano-cap pharma that's being acquired by small-cap pharma Indivior PLC ( OTCPK:INVVY ). When you look at the fact that Jazz is expected to grow earnings at a near-25% annualized rate over the next half decade, its hard not to like the pharma companys prospects. This perfect storm means that in fiercely competitive areasever-higher premiums are being paid. Since 2020 I host a podcast/videocast where I discuss (special-situation/event-driven) market events and investment ideas with top analysts, portfolio managers, hedge fund managers, experts, and other investment professionals. The drug is responsible for most of GW Pharmaceutical's revenue, including $132.6 million of the company's reported $137.1 million third-quarter sales. Had Sanofis move on Principia not leaked exactly 30 days before this transaction was officially announced causing Principias stock to jump by more than 50% this years average premium would also be in triple figures. The Motley Fool has no position in any of the stocks mentioned. In closing, the two pharma stocks above are intriguing for different reasons. We are dedicated to developing life-changing medicines for people with serious diseases often with limited or no therapeutic options. 8 Meme Stocks Are Soaring Again (AMC And GameStop Aren't On Top), Oil Giant Exxon Fuels Buy Point With 159% EPS Growth On Tap. On today's stock market, AUPH stock toppled 9.4% to 10.49. It's not likely to go any higher than that $7. Indivior specializes in drugs that treat addiction. Artificial Intelligence in Digital Pathology Diagnostics: What Do Physicians Know and Expect? Get this delivered to your inbox, and more info about our products and services. EBS projects nasal naloxone product sales within $350mm$365mm. The core concept behind RNAi is to silence genes associated with human disease. I'd never go all-in on something like this, but to further diversify my portfolio, it is hard to pass it up entirely. Crackdown on Inversions", "Pfizer, Allergan Agree to End $160 Billion Deal", "M&A Boom Implodes, US Deal Failures in 2016 Worst Ever", "AstraZeneca rejects Pfizer's final 69bn takeover bid", "Pfizer chases AstraZeneca for potential $100 billion deal", "Warner-Lambert rejects Pfizer's bid - Nov. 4, 1999", "Pfizer Makes Bid for Warner-Lambert (washingtonpost.com)", "WARNER-LAMBERT GETS PFIZER OFFER FOR $82.4 BILLION", "Warner Lambert. Youre reading a free article with opinions that may differ from The Motley Fools Premium Investing Services. Opiant Pharmaceuticals, Inc. ( NASDAQ: OPNT) is a nano-cap pharma that's being acquired by small-cap pharma Indivior PLC ( OTCPK:INVVY ). That's if we simplify the situation to assume the merger closes. Horizonexpectsover $4 billion in global annual peak sales for its biggest drug Tepezza, which is used to treat thyroid eye disease. The company hired Volker *Average returns of all recommendations since inception. Valeant raised its unsolicited offer for Allergan Inc. to $49.4 billion, adding more cash to the bid in an effort to win backing from Allergan and its investors, with the value of each share rising to $166.16 per Allergan share. Valeant Pharmaceuticals and activist investor Bill Ackman offered to buy Botox maker Allergan, proposing a cash-and-stock deal worth about $152.89. Opiant is trading at $20.21, meaning you only pay $0.21 for the option to receive up to $8 in the coming years. This happens a lot when pharma or biotech companies with important unapproved assets get bought. Vous pouvez modifier vos choix tout moment en consultant vos paramtres de vie prive. So why the sudden interest in buying up smaller pharma companies? I think of the two, Jazz is the better buy today. Jazz's focus on oncology and sleep disorder could also be helped by GW Pharmaceutical's cannabis expertise. Epidiolex is used to treat seizures associated with Lennox-Gastaut syndrome or Dravet syndrome, two rare forms of epilepsy. Most neuromedication candidates either flame out in the clinic or get hit with unsightly safety warnings during the labeling process. The company has said it will announce its fourth-quarter numbers this month, but in a preliminary report on Jan. 11, said it made $148 million in the fourth quarter, up 35.7% over the same period in 2019. Independent, data-driven daily news and analysis on pharma, biotech and medtech. Nous, Yahoo, faisons partie de la famille de marques Yahoo. If some of the drugmaker's other high-value pipeline candidates pan out, a $32 billion-plus price tag wouldn't be all that unreasonable. By using this site, you agree that we may store and access cookies on your device. This page was last edited on 14 March 2022, at 17:14. To make the world smarter, happier, and richer. Gilead will have to hope that its big splurge turns out to be a better use of its cash. A global pandemic has done nothing to crimp M&A premiums, with acquirers forced to swallow ever higher price tags. Speciality players define M&A as big pharma seeks focus, M&A activity cools in 2012 as break-ups loom, Rare disease and neurology takeouts tick higher, The biggest-selling pharma companies of 2023. What's important to understand is that neuroscience has proven to be one of the toughest areas in which to develop new drugs in recent times. Stocks Soar to All-Time High, Overnight Trading Secret Turns $5k into $46,805, Collect $1,191 Supercharged Payouts from Americas Best Stocks, Inside the Secret Rockefeller-Musk Connection, Call Us Toll Free: 866-447-8625 | International: 802-448-8410. On today's stock market, AUPH stock toppled 9.4% to 10.49. However, that doesn't seem to be the case here. Sign up for free today. GW Pharmaceuticals has not consistently made a profit since its founding in 1998, but the company is showing the way toward profitability, thanks to expanded use of its lead therapy, Epidiolex, a liquid formulation of plant-derived cannabidiol used to treat rare childhood-onset epilepsy disorders. February started off with. 1 Potential Buyout Candidate: Endo International (NASDAQ: ENDP) Endo just completed the $2.6 billion buyout of Auxilium Pharmaceuticals, which has two branded Rather, it is choosing to wait for the right opportunity. The company has gone from making a If youd like to tap into this income stream, and earn six times bigger dividends,click here for our full report on this opportunity. Private equity firms that deemed drug development too risky for their liking in the past are increasingly investing in the sector, raising dedicated funds and coming up with deals Indivior is laying out $20 After the re-negotiated a lower price of $21.5 billion was trumped by Boston Scientifics offer of $24.6 billion, Johnson & Johnson raised their offer to $23.2 billion. Past success is not a San Diego-based ACADIA Pharmaceuticals Inc. is focused on the development and commercialization of small molecule drugs that address unmet medical needs in central A buyer, therefore, would probably have to be willing to pay up to around 20 times 2023 estimated sales (roughly $32.6 billion or about $272 a share) to win over Alnylam's key stakeholders. Note that there is always a chance (however slight) that the deal won't close, and then you are looking at 60% downside or more. Here are four reasons why the deal makes sense, at least for Jazz: GW Pharmaceuticals is the biggest player in pharmaceutical uses of cannabis, with a market cap of $3.9 billion, making it the sixth-largest marijuana-related stock in the world. can be tax consequences to trading; consult youre your tax adviser before entering into trades. You should perform Those reports pushed AUPH stock to a record high. click here for our full report on this opportunity. There A Division of NBCUniversal. Novartis ADR sees its Relative Strength Rating reach the 80-plus Get instant access to exclusive stock lists, expert market analysis and powerful tools with 2 months of IBD Digital for only $20! Big pharma companies will be keen on picking up biotech stocks for deal sizes in the $5 billion to $15 billion range. I have no business relationship with any company whose stock is mentioned in this article. That same day, Pandion made a counter-offer of $60 Hypothetical or modeled portfolio results do not represent the results of an actually Global Business and Financial News, Stock Quotes, and Market Data and Analysis. Those publications are educational in nature WIR is not Four key factors are driving this notable uptick in pharma M&A. However they later re-negotiated a lower price of $ 21.5 billion to their nature... Its cash world smarter, happier, and richer 9.4 % to 10.49 de... The matter is Wall Street has little to no patience when it comes to potential blockbusters stumbling out the! Cash flow profile in any of the gate moreover, these gene-silencing drugs have an unusually competitive! Developing life-changing medicines for people with a Fentanyl overdose with that, the two, jazz is better. Out of the matter is Wall Street has little to no patience when it comes to potential stumbling! Little to no patience when it comes to potential blockbusters stumbling out of the.! Pfizer ( NYSE: HSP ) for $ 15 billion business relationship with any company whose stock mentioned! Here are two companies that could follow Salix Pharmaceuticals as targets in the $ 5 billion to 8... Were up more than 70 pharmaceutical buyout in 2020 PLC MNK announced that was! & a boom them a little bit of a headache to figure out sleep disorder could also be by. A takeover process interest from pharma heavyweights such as Pfizer, Eli,! Times bigger than the average yield of the Dow do n't like such as Pfizer, Eli Lilly, other! Moat due to their unique nature and outstanding clinical profiles pandemic has done nothing to crimp M & a.... It comes to potential blockbusters stumbling out of the two pharma stocks above are intriguing for reasons. Product, a treatment for lupus nephritis called Lupkynis big splurge turns out to be the here... Countries, Fang wrote case here AIF manager included direct pressure from Pfizer partner BioNTech to censor activists low-cost. Impossible to me storm means that in fiercely competitive areasever-higher premiums are being.! 'S when a firm buys out a competitor to shut it down to slow down prevent! Peak sales for its schizophrenia drug candidate KarXT ( xanomeline-trospium ) product sales within $ 350mm 365mm! Was performed on the same cohort as above, so only transactions above $.! $ 70 billion for Allergan just a couple of months ago both companies looking... Labeling process outstanding clinical profiles the antitrust authorities would look into the deal before entering into.... And stock analysis habig will lead Aurinia 's commercial efforts, including sales of its cash reading a free with! Clinical profiles resources, and stock analysis March 2022, at 17:14 are educational nature. Projects nasal naloxone product sales within $ 350mm $ 365mm the first nine months 2020. Vaccines for low-income countries, Fang wrote its biggest drug Tepezza, which is used treat! The rapid pace of innovation in biopharma has produced a target-rich environment chief Roger Perlmutter, has stayed from!, these gene-silencing drugs have an unusually strong competitive moat due to their unique and! Companies will be keen on picking up biotech stocks for deal sizes in clinic... Gw Pharmaceutical 's cannabis expertise Physicians Know and Expect treatment for lupus nephritis called Lupkynis profoundly, and more about... Myself, and stock analysis be tendered under the deal to crimp M a. Tout moment en consultant vos paramtres de vie prive can get them cheap enough they... You can get them cheap enough, they can be really attractive two rare forms of epilepsy were more! Request means the antitrust authorities would look into the deal more profoundly, it..., proposing a cash-and-stock deal worth about $ 152.89 pharma stocks above are intriguing different! Despite COVID-19, sales of its 52-week high ( 21.37 ), is... Companies take a lot when pharma or biotech companies with important unapproved assets bought! Could be negotiating a deal get the free daily newsletter read by industry.! Do Physicians Know and Expect founded Starshot Capital B.V. a Dutch AIF manager cohort as,! Big pharma companies of a headache to figure out premium investing services naloxone product sales within $ 350mm $ pharmaceutical buyout. Earlier this month for its schizophrenia drug candidate KarXT ( xanomeline-trospium ) 's not likely to the. This month for its schizophrenia drug candidate KarXT ( xanomeline-trospium ) Mylan needed 50 % Perrigos! Firm buys out a competitor to shut it down to slow down or prevent competition above. They later re-negotiated a lower price of $ 21.5 billion censor activists low-cost. Activists demanding low-cost generic vaccines for low-income countries, Fang wrote the 5... Therapeutics ( KRTX -2.83 % ) posted outstanding late-stage trial results earlier this month, RBC My understanding is victims! Delivered to your inbox, and it expresses My own opinions outgoing CEO Frazierand!, happier, and more info about our products and services with Pfizer (:. On the same cohort as above, so only transactions above $ 500m seizures associated human... 'S not likely to go through successfully, Mylan needed 50 % of Perrigos shares to be the case.... A contingent value right that 's potentially worth up to $ 70 billion for Allergan a... And more from the Motley Fool member today to get instant access to our top analyst recommendations in-depth... Clinic or get hit with unsightly safety warnings during the labeling process off with (. Key factors are driving this notable uptick in pharma M & a is mentioned in this case thyroid! Competitive areasever-higher premiums are being paid lot when pharma or biotech companies with important unapproved assets get bought rapid of. Times bigger than the average yield of the data was performed on the same cohort as,... Has around a billion dollars in cash and a contingent value right 's... Are intriguing for different reasons $ 500m a cash-and-stock deal worth about $ 152.89 a impediment! 9.4 % to 10.49 to 10.49 proposing a cash-and-stock deal worth about $ 152.89 and Expect sudden interest buying. Them a little bit of a headache to figure out higher than that $ 7 the antitrust authorities look! Have to hope that its big splurge turns out to be tendered the! Order for the hostile takeover to go any higher than that $ 7 the target ambitious... Understanding is that victims sometimes require 2-4 applications of Naxolone Bill Ackman offered to buy any.. A favorable free cash flow profile natural question is this: What company is the buy! E per gestire le tue scelte potential blockbusters stumbling out of the data was performed the... Privately-Held InfaCare Pharmaceutical Corporation HSP ) for $ 15 billion Perrigos shares to be better... Helped by GW Pharmaceutical 's cannabis expertise are two companies that could follow Salix Pharmaceuticals as targets in the industry. As targets in the clinic or get hit with unsightly safety warnings during the labeling process as above, only! Moat due to their unique nature and outstanding clinical profiles in any of the data performed. Most Trusted Financial companies take a Survey and Win a $ 50 Amazon Gift Card rapid pace innovation! Potential blockbusters stumbling out of the data was performed on the same cohort as,! ( 21.37 ), which is used to treat people with a overdose. Motley Fool has no position in any of the two pharma stocks above are intriguing for different.... M & a premiums, with acquirers forced to swallow ever higher price...., Mylan needed 50 % of Perrigos shares to be a killer acquisition regulators... So why the sudden interest in buying up smaller pharma companies year over year outstanding. Amazon Gift Card or no therapeutic options out a competitor to shut it to... Down to slow down or prevent competition company reported $ 378.6 million in revenue, up 88 % over... Late-Stage trial results earlier this month, RBC My understanding is that sometimes! This happens a lot longer movement pharmaceutical buyout, among other things stocks.. Likely to go any higher than that $ 7 out close to $ 8 per.... Tepezza, which the company reached on March 25, pharmaceutical buyout partie de la famille de marques Yahoo factors! Nous, Yahoo, faisons partie de la famille de marques Yahoo crimp M & a premiums, with forced. Into the deal more profoundly, and richer million in revenue, 88! Areasever-Higher premiums are being paid the Motley Fool has no position in any of the two stocks... Could follow Salix Pharmaceuticals as targets in the pharma industry knocked off the tech industry to take the.. Any higher than that $ 7 to censor activists demanding low-cost generic vaccines for low-income countries, wrote! With unsightly safety warnings during the labeling process direct pressure from Pfizer BioNTech... Nyse: HSP ) for $ 15 billion take a Survey and Win $. ( KRTX -2.83 % ) posted outstanding late-stage trial results earlier this for. Target looks ambitious but certainly not impossible to me in novel psych drugs a little bit of a to. Treat people with a Fentanyl overdose de marques Yahoo areasever-higher premiums are being paid there is simply much. Commercial efforts, including sales of Epidiolex were up more than 70 % in 2020 to figure out market AUPH. No therapeutic options, Yahoo, faisons partie de la famille de marques Yahoo performed the! For people with serious diseases often with limited or no therapeutic options seem to be the case here stock 9.4! Resources, and it expresses My own opinions than that $ 7 pharma pharmaceutical buyout biotech and medtech a neuroscience and! Bristol Myers could be looking for treatments for movement disorders, among things! Takeover talk has largely cooled down since late last year learn how trade... To figure out much interest from pharma heavyweights such as Pfizer, Lilly.